Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome

Topol, 1999, Platelet GP IIB-IIIa blockers, Lancet, 353, 227, 10.1016/S0140-6736(98)11086-3 Batchelor, 2002, Circulation, 106, 1470, 10.1161/01.CIR.0000029744.01096.1F Valgimigli, 2004, The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE trial, J Am Coll Cardiol, 44, 14, 10.1016/j.jacc.2004.03.042 King, 2016, Glycoprotein IIb/IIIa inhibitors: the resurgence of tirofiban, Vascul Pharmacol, 78, 10, 10.1016/j.vph.2015.07.008 1998, A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina, N Engl J Med, 338, 1498, 10.1056/NEJM199805213382103 U.S. Food and Drug Administration. Clinical Study Report MK-0383. A randomized, parallel, double-blind study to investigate the safety and clinical efficacy of MK-0383 vs. heparin in patients with unstable angina/non-Q-wave myocardial infarction (PRISM). Protocol No. 011–016. September 1997. 1985, The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings, N Engl J Med, 312, 932, 10.1056/NEJM198504043121437 Eikelboom, 2001, Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study, Circulation, 103, 643, 10.1161/01.CIR.103.5.643 McClure, 1999, Clinical significance of thrombocytopenia during a non–ST-elevation acute coronary syndrome: the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy (PURSUIT) trial experience, Circulation, 99, 2892, 10.1161/01.CIR.99.22.2892 Yeh, 2007, Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes, Am J Cardiol, 100, 1734, 10.1016/j.amjcard.2007.07.036 Wang, 2009, Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice, Circulation, 119, 2454, 10.1161/CIRCULATIONAHA.108.827162 Jneid, 2012, J Am Coll Cardiol, 60, 645, 10.1016/j.jacc.2012.06.004 Amsterdam, 2014, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 130, 2354, 10.1161/CIR.0000000000000133 Windecker, 2014, Eur Heart J, 35, 2541, 10.1093/eurheartj/ehu278 Roffi, 2016, Eur Heart J, 37, 267, 10.1093/eurheartj/ehv320 Gore, 2009, Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]), Am J Cardiol, 103, 175, 10.1016/j.amjcard.2008.08.055 Reese, 2010, Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods, Blood, 116, 2127, 10.1182/blood-2010-03-276691 Aster, 2009, Drug-induced immune thrombocytopenia: pathogenesis, diagnosis and management, J Thromb Haemost, 7, 911, 10.1111/j.1538-7836.2009.03360.x Bougie, 2002, Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand occupied GPIIb/IIIa, Blood, 100, 2071, 10.1182/blood.V100.6.2071 Bougie, 2012, Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin, Blood, 119, 6317, 10.1182/blood-2012-01-406322 Valgimigli, 2010, Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials, Eur Heart J, 31, 35, 10.1093/eurheartj/ehp376 Valgimigli, 2005, Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial, JAMA, 293, 2109, 10.1001/jama.293.17.2109 Valgimigli, 2008, Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial, JAMA, 299, 1788, 10.1001/jama.299.15.joc80026 Dunne, 2013, A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study, BMC Pharmacol Toxicol, 14, 1, 10.1186/2050-6511-14-1 Fusier, 2003, Medicines containing pharmaceutical excipients with known effects: a French review, Pharm World Sci PWS, 25, 152, 10.1023/A:1024815412228 Mumoli, 2011, Allergic reaction to Croscarmellose sodium used as excipient of a generic drug, QJM, 104, 709, 10.1093/qjmed/hcq175 Reiffel, 2000, Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice, Am J Cardiol, 85, 46D, 10.1016/S0002-9149(00)00906-1 Patel, 2009, Pharmaceutical Salts: A formulation trick or a clinical conundrum?, Br J Cardiol, 16, 281